Trial Profile
An open trial of a Cognitive Behavioural Therapy (CBT)-based smoking cessation plus Varenicline intervention in people with a psychotic disorder
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Jun 2016
Price :
$35
*
At a glance
- Drugs Varenicline (Primary)
- Indications Psychotic disorders; Smoking withdrawal
- Focus Therapeutic Use
- Sponsors Pfizer
- 08 Jun 2016 Status changed from not yet recruiting to completed.
- 27 May 2009 New trial record